Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma.

The Journal of experimental medicine - 6 Aug 2018

Stolte Björn, Iniguez Amanda Balboni, Dharia Neekesh V, Robichaud Amanda L, Conway Amy Saur, Morgan Ann M, Alexe Gabriela, Schauer Nathan J, Liu Xiaoxi, Bird Gregory H, Tsherniak Aviad, Vazquez Francisca, Buhrlage Sara J, Walensky Loren D, Stegmaier Kimberly

Abstract excerpt

Ewing sarcoma is a pediatric cancer driven by EWS-ETS transcription factor fusion oncoproteins in an otherwise stable genomic background. The majority of tumors express wild-type TP53, and thus, therapies targeting the p53 pathway would benefit most patients. To discover targets specific for TP53 wild-type Ewing sarcoma, we used a genome-scale CRISPR-Cas9 screening approach and identified and validated MDM2,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to CRISPR-Associated Protein 9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dipeptides

Share to Drug Synergism

Share to Peptides, Cyclic

Share to Sarcoma, Ewing

Share to Thiophenes

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 30045945
DOI: 10.1084/jem.20171066
PMCID: PMC6080915

Genes

USP7
MDM2
MDM4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma.PMID 30045945Read ↗

PPM1D is a neuroblastoma oncogene and therapeutic target in childhood neural tumorsSemantic proximity Read ↗

Dysregulation of the p53 pathway provides a therapeutic target in aggressive pediatric sarcomas with stem-like traitsSemantic proximity Read ↗

MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid TumorsSemantic proximity Read ↗

Integrated genetic and pharmacologic interrogation of rare cancersSemantic proximity Read ↗

The Development of p53-Targeted Therapies for Human CancersSemantic proximity Read ↗

Genome‐wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild‐type TP53 and receptor tyrosine kinase genesSemantic proximity Read ↗

Targeting the p53 pathway to treat Malignant Rhabdoid and Atypical Teratoid Rhabdoid TumorsSemantic proximity Read ↗

A CRISPR-drug perturbational map for identifying compounds to combine with commonly used chemotherapeuticsSemantic proximity Read ↗

Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.Semantic proximity Read ↗

A CRISPR-drug perturbational map for identifying new compounds to combine with commonly used chemotherapeuticsSemantic proximity Read ↗

Mitochondrial Dysfunction is a Driver for SP-2509 Drug Resistance in Ewing SarcomaSemantic proximity Read ↗

p53 Pathway Inactivation Drives SMARCB1 -deficient p53 -wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 InhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.